For US Health Care Professionals Only
For patients with cGVHD aged ≥12 years after failure of any 2 prior systemic therapies.1
REZUROCK is the first and only treatment for cGVHD that selectively inhibits the ROCK2 pathway. REZUROCK is an immunomodulator that is designed to downregulate inflammation and fibrosis.1-3
The ORRb,c was 75% at the recommended dose of 200 mg once daily (n=65) in the pivotal ROCKstar study.
REZUROCK was evaluated in a real-world population of patients with cGVHD.1,5,d
aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
bBased on a final analysis by the FDA as seen through cycle 7 day 1 (n=65).1
cProportion of patients who achieved CR or PR according to the 2014 NIH cGVHD Consensus Criteria.1,5
dROCKstar study select baseline patient characteristics (200-mg once-daily arm): Median age of 53 years (range, 21-77); male, n=42 (64%); median of 3 prior lines of systemic therapy; median of 25 months (range, 2-162) from cGVHD diagnosis to enrollment; median prednisone-equivalent dose at enrollment of 0.20 mg/kg/d (range, 0.03-0.95); concomitant PPI use, n=33 (50%); ≥4 organs involved, n=33 (50%); previous aGVHD, n=42 (64%); refractory to prior line of systemic therapy, n=44 (79%e); NIH-defined disease severity: n=46 (70%) severe, n=18 (27%) moderate, n=2 (3%) mild. Prior systemic therapies included corticosteroids (prednisone), n=65 (99%); tacrolimus, n=40 (61%); ECP, n=31 (47%); ibrutinib, n=22 (33%); and ruxolitinib, n=20 (30%).5,6
eDenominator excludes patients with unknown status.1
A ROCK2 inhibitor designed to address the
associated with cGVHD1-3
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CR, complete response; ECP, extracorporeal photopheresis; FDA, US Food and Drug Administration; MOA, mechanism of action; NCCN, National Comprehensive Cancer Network® (NCCN®); NIH, National Institutes of Health; ORR, overall response rate; PPI, proton pump inhibitor; PR, partial response; ROCK2, rho-associated coiled-coil-containing protein kinase-2.
References: 1. REZUROCK. Package insert. Kadmon Pharmaceuticals, LLC. 2. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814-16819. doi:10.1073/pnas.1414189111 3. Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144-2154. doi:10.1182/blood-2015-10-678706 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation. V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 24, 2025. To view the most recent and complete version of the guideline, go online to http://NCCN.org 5. Cutler C, Lee SJ, Arai S, et al; on behalf of the ROCKstar Study Investigators. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278-2289. doi:10.1182/blood.2021012021 6. Data on file. Sanofi.
REZUROCK® (belumosudil) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Please click here for full Prescribing Information.
Please click here for full Prescribing Information.
REZUROCK® (belumosudil) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
REZUROCK® (belumosudil) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Please click here for full Prescribing Information.
Please click here for full Prescribing Information.
REZUROCK® (belumosudil) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
REZUROCK® (belumosudil) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Please click here for full Prescribing Information.
Please click here for full Prescribing Information.
REZUROCK® (belumosudil) is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.